On October 28, 2020 Data presented by Invitae (NYSE: NVTA), a leading medical genetics company, reported at the American Society of Human Genetics (ASHG) Virtual Meeting found one in ten men with prostate cancer harbor genetic changes linked to hereditary cancer syndromes and three-quarters of those patients met criteria for changes in cancer management or treatment based on their genetic findings (Press release, Invitae, OCT 28, 2020, View Source [SID1234569207]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Invitae’s (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation)

The study of more than 4,000 men with prostate cancer also found no statistical difference in the rate of cancer-causing genetic changes based on stage of disease, suggesting common criteria used to restrict testing would miss clinically important changes for many patients and their families.

"These new findings provide further evidence of the strong genetic associations with prostate cancer. It’s clear that we must continue to explore how we can make genetic testing more available and accessible for men with prostate cancer, which will support treatment decisions through targeted therapies, clinical trial eligibility and additional management recommendations," said Sarah Nielsen, M.S., L.C.G.C., the lead author on the study. "Not only does increased genetic testing benefit the patient, but it also lends insight into family health risks, and particularly for female relatives, who might face an unknown higher risk of breast and ovarian cancers."

The study also looked at the rate of genetic changes based on reported ethnicity. Study participants included greater representation of patients reporting African-American and Hispanic ethnicity than most studies that have examined the inherited genetics of prostate cancer patients. Researchers found lower positivity rates among men reporting African-American (6.2%) and Asian (6.7%) ethnicity, while the rates of genetic variants of uncertain significance were highest in these two populations (58.9% and 66.7%, respectively), highlighting the need to expand testing in these populations to better understand and normalize unique genetic variations.

Participants in the study received testing through Invitae’s sponsored hereditary prostate cancer testing program which provides no-charge testing for men with prostate cancer.

On October 28, 2020 Spectrum Pharmaceuticals (NasdaqGS: SPPI) a biopharmaceutical company focused on novel and targeted oncology therapies, reported it will host a conference call to discuss the third quarter 2020 financial results and provide a corporate update on Wednesday, November 4, 2020 at 4:30 p.m. Eastern/1:30 p.m. Pacific (Press release, Spectrum Pharmaceuticals, OCT 28, 2020, View Source [SID1234569205]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call and Webcast:

Wednesday, November 4, 2020 @ 4:30 p.m. Eastern/1:30 p.m. Pacific

Domestic:

(877) 837-3910, Conference ID# 1281757

International:

(973) 796-5077, Conference ID# 1281757

The conference call will also be available from the Investor Relations section of the company’s website at View Source and will be archived there shortly after the live event.

On October 28, 2020 Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) reported that it will report its third quarter 2020 financial results on Thursday, November 5, 2020 (Press release, Deciphera Pharmaceuticals, OCT 28, 2020, View Source [SID1234569204]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In connection with the earnings release, Deciphera’s management team will host a live conference call and webcast at 4:30 PM ET on Thursday, November 5, 2020, to discuss the Company’s financial results and provide a corporate update.

The conference call may be accessed by dialing (866) 930-5479 (domestic) or (409) 216-0603 (international) and referring to conference ID 6048987. A webcast of the conference call will be available in the "Events and Presentations" page in the "Investors" section of the Company’s website at View Source The archived webcast will be available on the Company’s website approximately two hours after the conference call and will be available for 30 days following the call.

On October 28, 2020 Researchers with Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center (UHCMC) reported that they have secured $4 million in funding from the National Institutes of Health (NIH)/National Cancer Institute (NCI) to establish an HIV-associated Malignancy Research Center (HAMRC) focused on lung cancer in East Africa (Press release, Case Western Reserve University, OCT 28, 2020, View Source [SID1234569203]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The team will collaborate with Ugandan and Tanzanian researchers at the Joint Clinical Research Centre in Kampala, Makerere University Lung Institute, Uganda Cancer Institute, Mulago National Hospital, National Institute for Medical Research (NIMR), Muhumbili National Hospital and the Ocean Road Cancer Institute. The HAMRC will investigate novel approaches to characterize lung cancer epidemiology, somatic mutation burden, HIV and accelerated aging, and radiological features of lung cancer and the relationship to HIV-1 infection.

The focus of this new research center includes establishing national lung cancer diagnostic referral networks in Uganda and Tanzania, teleradiology telepathology, technology transference, and training of early career investigators and personnel.

This cross-continental effort is led by:

Robert A. Salata, Case Western Reserve/UHCMC;
Stan Gerson, Case Western Reserve;
Bruce Kirenga, Makerere University Lung Institute; and
Sayoki Mfinanga, National Institute for Medical Research, Muhimbili Centre, Tanzania.
The CCCC, which has a history of coordinating large, multi-institution projects, will provide administrative support, while the Joint Clinical Research Centre is the central site of research activity.

This five-year effort will take a comprehensive approach to better define the genetic and molecular determinants of lung cancer and how they impact—or are impacted by—HIV, a condition prevalent in these countries. This research aims to develop diagnostic computational imaging algorithms to discern lung cancer from other types of respiratory infections—especially tuberculosis, which is frequent in these African countries among patients with and without HIV.

The HAMRC will harness Case Western Reserve’s Center for Computational Imaging and Personalized Diagnostics (CCIPD) expertise in artificial intelligence (AI) to study lung cancer and the relationship to HIV-1 infection using radiological scans.

"We know from prior research that there are correlations between HIV and higher rates of lung cancer, and we hypothesize that HIV with its immunosuppression contributes to premature immunological aging, a known risk factor for lung cancer," said Salata, chair of Case Western Reserve’s Department of Medicine and program director of the UH Roe Green Center for Travel Medicine & Global Health. "We will use advanced imaging capabilities coupled with novel AI and computational approaches to support accurate and timely diagnosis."

Case Western Reserve and Makerere University have forged a research collaboration for 32 years, resulting in breakthroughs in characterizing the epidemiology and molecular-level mechanisms of conditions including tuberculosis, HIV and various forms of cancer.

"Collaborations like this one are part of the global priorities of the National Cancer Institute to advance the global medical community’s understanding of the interrelations between complex diseases and cancer, and how to treat them appropriately," said Gerson, CCCC director and interim dean of the School of Medicine. "While our focus for this series of projects is on the inter-relatedness of HIV, including increased risks for cancer, we anticipate that findings will inform diagnostic capabilities and personalized treatment for many types of cancer that present uniquely or that are accelerated in immunocompromised patients."

Kirenga, director and pulmonologist at the Makerere University Lung Institute, and Mfinanga, NIMR director, have worked together on various large-scale, multi-country projects since 2009, notably on tuberculosis, which has informed the global community’s understanding of this and other infectious disease.

"This collaboration with CWRU and the Case Comprehensive Cancer Center builds on decades of relationships that have advanced understanding worldwide about diseases that do not recognize maps and borders," Kirenga said. "The global community of cancer and infectious disease translational researchers recognize the importance of deepening our understanding of how complex conditions inform one another. This collaboration builds on a history of work that has resulted in better diagnostics and treatment for many conditions that touch thousands of lives worldwide."

Research team leadership includes:

Anant Madabhushi, director of CCIPD and the Donnell Institute Professor of Biomedical Engineering, Case Western Reserve;
Afshin Dowlati, professor of medicine at Case Western Reserve and director of the Thoracic Oncology Program at University Hospitals Seidman Cancer Center;
Joseph Willis, professor of medicine at Case Western Reserve and vice chairman of Pathology for Translational Research at University Hospitals Cleveland Medical Center; and
Simon Kasasa, senior lecturer of epidemiology and biostatistics at Makerere University.

On October 28, 2020 ChromaDex Corp. (NASDAQ:CDXC) reported that it will hold a conference call on Wed., November 4, 2020 at 4:30 p.m. ET to discuss its financial results for the third quarter ended September 30, 2020 (Press release, ChromaDex, OCT 28, 2020, View Source [SID1234569202]). The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investor Conference Call:

ChromaDex management will host an investor conference call to discuss the third quarter results and provide a general business update on Wed., November 4, at 4:30 p.m. ET.

Participants should call in at least 10 minutes prior to the call. The dial-in information is as follows:

Date: Wed., November 4, 2020
Time: 4:30 p.m. ET (1:30 p.m. Pacific time)
Toll-free dial-in number: 1-833-979-2703
International dial-in number: 236-714-2223
Conference ID: 4699759
Webcast link: ChromaDex Third Quarter 2020 Earnings Conference Call

The conference call will be broadcast live and available for replay here and via the investor relations section of the Company’s website at www.chromadex.com.

A replay of the conference call will be available after 7:30 p.m. ET.